Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.

Cell reports. Medicine - 19 May 2026

Pimenta Ruan, Maurer Stefanie, Zhong Xiaoxuan, Taciane da Silva Bortoleti Bruna, Quasem Sophia, Ribeiro de Lima Brandão Luiza, Marcellino Bridget, Dutta Anindita, Arriaga Juan M, Mascarenhas John, Ferrari de Andrade Lucas

Abstract excerpt

Anti-MICA/B antibodies that inhibit the shedding hold promise for cancer immunotherapy and are in phase 1 clinical trials. Although MICA/B-shedding inhibition promotes natural killer (NK) cell-driven immunity by NKG2D engagement, the Fc enables antibody-dependent cellular cytotoxicity. We, therefore, engineer the Fc of an anti-MICA/B antibody (clone 7C6) through GAALIE mutations that increase the binding affinity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy
Share to Antibody-Dependent Cell Cytotoxicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Disease Models, Animal

Share to Hematologic Neoplasms

Share to Histocompatibility Antigens Class I

Share to Immunoglobulin G

Share to Killer Cells, Natural

Source

Open in PubMed Open full text

Identifiers

PMID: 41999749
DOI: 10.1016/j.xcrm.2026.102753
PMCID: PMC13198289

Genes

MICA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A MICA/B GAALIE-mutant antibody elicits potent natural killer cell-driven immunity in solid and hematologic malignancy models.PMID 41999749Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlSemantic proximity Read ↗

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.Semantic proximity Read ↗

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor controlSemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.Semantic proximity Read ↗

FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesSemantic proximity Read ↗

Fc₉₅, a next-generation Fc variant, achieves exceptional ADCC potency by linking affinity enhancement to intrinsic afucosylationSemantic proximity Read ↗

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myelomaSemantic proximity Read ↗

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.Semantic proximity Read ↗

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cellsSemantic proximity Read ↗

Selective decoupling of IgG1 binding to viral Fc receptors restores antibody-mediated NK cell activation against HCMVSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.